Absci Stock Buy or Sell? ABSI Stocks Forecast

Market Capitalization: 434 952 000 $
EBITDA: -75 683 000 $
Price to Earnings: None
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.686
Trailing PE: -
Forward PE: -
Shares Outstanding: 92938000






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Absci Stock Buy or Sell? ABSI Stocks Analytic Forecasts

Updated on February 27, 2024 (10:19)

Absci Corporation (ABSI prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the ABSI stock market. Experts share their opinions on what to expect from the Absci Corporation stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Absci stocks.

Absci Corporation Stock Market Experts’ Analysis and Forecasting – Sell or Buy ABSI Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Edmund Ingham and is titled

“Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out”

is published on January 10 (2022) and has 4 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • Absci, a Vancouver-based drug discovery company that IPOd in July last year, has seen its market cap fall from >$2bn, to $665m at the time of writing.
  • This isn’t unusual for a drug discoverer/developer – Abcellera, also based in Vancouver, has seen its stock fall >80% while even Ginkgo Bioworks stock is -30% since IPO.
  • Absci has recently announced a partnership with Merck for up to three candidates which could be worth up to $640m, if all milestones are met.
  • That’s not necessarily likely but it does serve as validation of the young company’s technology and approach. Merck is revamping its R&D and Absci could make itself an indispensable part of that.
  • The deal will not do much for Merck in the short term, but it may help push Absci’s valuation higher – shares were 44%-plus on the news. Investing with a five-year investment horizon may offer a good ROI.

The author starts his analytic review with the following:

Investment Thesis – Market Has Depressed AI Drug Discovery Firms’ Valuations Absci (NASDAQ:ABSI) is a biotech focused on early stage drug development that IPO’d in July last year, raising ~$230m via the issuance of 12.5m shares at a price of $16.

The opinion of the author can be considered quite authoritative.
The number of 8482 followers confirms this.
Edmund Ingham is the contributor of experts community
since 2018 and has 449 works published.


One more noteworthy article is written by CEO Interviews under the title

“IPO Day With Absci CEO Sean McClain – The Google Of Synthetic Biology (Video)”

on July 22 (2021) and has 1 likes. The expert reflects trend of the market.

Нis theses make you think about whether to add ABSI stocks to your investment portfolio or not, and helps to work out your own Absci stock selling strategies:

  • Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today.
  • CEO Sean McClain discusses the emotion around going public, acquisitions in the time of Covid and being a technology driven company.
  • Providing tech solutions for pharma partners and what metric is key to watch over the next year.

CEO Interviews starts analysis with such words:

CEO Interviews has already 1790 followers, which shows, he is the one who cares for his words.
The contributor of experts community since 2021. Has published at least 204 articles.


Another analysis presented by Donovan Jones came out on July 20 (2021). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for ABSI stocks. It sounds like

“AbSci Proposes Terms For $200 Million IPO”

Article has got 2 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Absci Corporation, the expert says the following:

  • AbSci has filed to raise $200 million in a U.S. IPO.
  • The firm is commercializing a biologic development platform.
  • ABSI has promise but is still at a very early stage of commercialization and further development of its technologies and business model, so I’ll watch the IPO from the sidelines.

And here, what comes first:

Quick Take AbSci (NASDAQ:ABSI) has filed to raise $200 million in an IPO of its common stock, according to an S-1/A registration statement.

This author is very popular among the auditory. He has 18772 followers.

Donovan Jones is the contributor of experts community since 2016 and has at least 3790 analytic reviews published.


The Share Price of Absci Corporation (ABSI) for now

What analysts predict: $5.33
52-week high/low: $5.47 / $1.111

50/200 Day Moving Average: $3.833 / $2.167

The average stock price over the previous 50/200 days. For Absci stocks, the 50-day moving average is the resistance level for now. For ABSI stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for ABSI stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.